The FDA clears Zeltiq Aesthetics' (ZLTQ +0.6%) entire suite of CoolSculpting applicators to treat thighs. Previously, it was approved to treat only the abdomen and flanks.
In clinical studies 86% of patients reported a visible reduction in outer thigh fat 16 weeks post treatment and were satisfied with the results.
Consensus estimates for Q1 and Q2 are a loss of $0.15/share on revenues of $27.5M and a loss of $0.07/share on revenues of $33.7M, respectively.
Consensus views for 2014 and 2015 are a loss of $0.36/share on revenues of $136.5M and a loss of $0.01/share on revenues of $161.2M, respectively.
164 mutual funds have positions, up from 83 a year earlier.